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On 23 October 2014, the a-melanocyte-stimulating hormone (a-MSH) ana-log afamelanotide (Scenesse) attained 
approval as a first-in-class drug for patients with 
adult erythropoietic protoporphyria (EPP) who 
are extremely intolerant of UV and visible light. 
This successful drug-development program is 
the consequence of a determined effort to trans-
late extensive basic research efforts.
a-MSH was originally characterized as a 
pituitary-derived inducer of pigmentation (Harris 
and Lerner, 1957). Notably, Lerner and co-work-
ers were also the first to assess intradermally and 
intramuscularly injected a-MSH in patients with 
vitiligo. The clinical effect was limited to some 
perifollicular pigmentation, and subsequent 
attempts with adrenocorticotropin-like peptides 
were never encouraging enough to bring these 
melanocortin peptides into daily practice in der-
matology (reviewed in Böhm, 2010). The reason 
for the limited clinical usefulness of a-MSH lies 
in its chemical structure—the tridecapeptide is 
too big for transcutaneous delivery; also, it rap-
idly degrades in the gastrointestinal tract when 
taken orally. In the presence of human plasma, 
the half-life of a-MSH is less than 30 minutes 
(Eberle, 1988). One possible strategy to over-
come this problem is chemical modification of 
the peptide without affecting the message and 
signal sequences required for the melanotropic 
effect of a-MSH. Among the plethora of MSH 
peptides tested by Hruby and co-workers, Nle-d-
Phe7-a-MSH (NDP-a-MSH) emerged as one of 
the most potent and long-acting pigment-induc-
ing synthetic melanocortin peptides (Sawyer et 
al., 1980). The first clinical studies in the 1990s 
revealed that local subcutaneous injections of 
NDP-a-MSH increase skin pigmentation (Levine 
et al., 1991; Barnetson et al., 2006).
Interestingly, anti-inflammatory and immuno-
modulatory effects were soon recognized during 
the functional characterization of a-MSH and 
found to reside within its C-terminal-tripeptide 
sequence (reviewed in Catania and Lipton, 
1993). However, pharmaceutical exploitation 
of KPV has been unsuccessful until now. The 
field of melanocortin research rapidly ex panded 
on cloning of the MC-Rs by Cone’s group 
(Mountjoy et al., 1992). The five MC-Rs (MC-1-
5R) belong to the superfamily of the G-protein-
coupled receptors with seven transmembrane 
domains and differ with regard to their binding 
affinities for melanocortins. The human MC-1R 
binds a-MSH and adrenocorticotropin with 
similar affinity. Investigating various cell types 
and tissues with MC-R subtype–specific probes 
in combination with functional studies allowed 
identification of several novel targets of a-MSH 
within the skin and beyond.
The main function of a-MSH within the skin 
becomes most apparent during UV-induced tan-
ning. Sun exposure is a prototypical environ-
mental stressor and increases expression of the 
proopiomelanocortin (POMC) as well as secre-
tion of a-MSH in the skin (Schiller et al., 2004). 
The mechanism behind this phenomenon is 
complex and involves on one hand UV-induced 
activation of the tumor suppressor gene prod-
uct p53 that subsequently binds to the POMC 
promoter in keratinocytes and turns on a-MSH 
expression (Cui et al., 2007). On the other hand, 
proinflammatory cytokines and mediators, 
some of them also players of the classical hypo-
thalamic–pituitary–adrenal axis, orchestrate 
UV-mediated POMC expression and a-MSH 
secretion within the skin (reviewed in Slominski 
et al., 2000). Melanocytes that express MC-1R 
most abundantly subsequently respond to 
UV-induced a-MSH expression with increased 
melanogenesis, proliferation dendrite formation, 
and melanin transfer to keratinocytes.
The physiological role of MC-1R in the con-
text of UV-induced pigmentation is highlighted 
by the finding of polymorphisms in the MC1R 
gene that are responsible for red hair and pale 
skin type. Carriers of loss-of-function alleles of 
MC1R have a higher risk for the development 
of melanoma and nonmelanoma skin cancer. 
Interestingly, this appears to be only partially 
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dependent on the impact of MC-1R on skin pigmentation 
(Beaumont et al., 2009). Accordingly, a-MSH has been found 
to directly reduce the extent of UVB-induced genotoxic 
stress in melanocytes (for example, to reduce the amount of 
cyclopyrimidine dimers). In individuals with loss-of-function 
MC1R alleles, this cytoprotective effect of a-MSH is lost 
(reviewed in Abdel-Malek et al., 2008)
Our picture of a-MSH in the skin, however, would be 
incomplete when leaving out the majority of other cell 
types responding to this molecule (reviewed in Böhm et al., 
2006). In many of the above cell types, a-MSH was shown 
to suppress the activation of the transcription factor NF-kB 
a-MSH and thereby modulate production of proinflam-
matory cytokines and expression of adhesion molecules 
(reviewed in Brzoska et al., 2008). Among the most recent-
ly identified human target cells of a-MSH are basophilic 
granulocytes (Böhm et al., 2012) and T cells (Loser et al., 
2010; Auriemma et al., 2012), both key players of the adap-
tive immune system that orchestrate allergic and inflamma-
tory responses of the skin and mucosal membranes. Studies 
of these nonmelanocytic cells of the skin further extended 
our current view of the cytoprotective armamentarium of 
a-MSH. For example, a-MSH directly upregulates nuclear 
factor E2-related factor 2, a transcription factor crucially 
involved in cellular redox homeostasis and a regulator of 
antioxidative enzymes like heme oxygenase 1 (Kokot et al., 
2009a, 2009b) (see Figure 1).
The pleiotropic cytoprotective properties of a-MSH pro-
vided the rationale for exploiting melanocortins as a new 
treatment in EPP. EPP is a rare autosomally inherited disease 
of porphyrin biosynthesis that is caused by mutations of fer-
rochelatase. As a consequence, the photosensitizer proto-
porphyrin IX accumulates in the skin, resulting in absolute 
sunlight intolerance. Upon sun exposure, EPP patients expe-
rience immediate, severe pain with subsequent erythema 
and edema. There is no effective therapy for this orphan 
disease, and often the only way that affected patients can 
prevent these symptoms is to strictly avoid daylight (Minder 
and Schneider-Yin, 2015). Using a sustained-release resorb-
able implant formulation that delivers 16 mg of NDP-a-MSH 
(afamelanotide), a pilot phase II trial was performed with five 
patients with EPP. The implant was administered subcutane-
ously, twice, 60 days apart. In all five patients, the time to 
provoke pain with an artificial xenon light source emitting 
UV light above 385 nm was significantly prolonged and 
associated with an increase in melanin density (Harms et al., 
2009). Additional phase II trials indicated beneficial effects 
of afamelanotide in patients with solar urticaria, acne, and 
vitiligo and confirmed a good safety profile as well (Haylett 
et al., 2009; Böhm et al., 2014; Lim et al., 2015).
Importantly, the initially observed promising effects of 
afamelanotide in EPP patients have been extended in several 
phase II and III trials (http://www.clinuvel.com/erythropoiet-
ic-protoporphyria). The results of these trials were significant 
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Figure 1. Afamelanotide reduces tissue damage and pain resulting from sun exposure in EPP patients. UVA and UVB damage DNA directly and UVA 
also causes oxidative damage, releasing reactive oxygen species (ROS). Visible wavelengths, particularly the Soret band (400–410 nm), are absorbed 
by protoporphyrin IX (PPIX), generating more ROS. The resulting inflammation and nerve damage causes pain and swelling in the skin of EPP patients. 
Afamelanotide, injected subcutaneously in a sustained release formulation at 60-day intervals, is distributed systemically and binds MC-1 receptors. Increased 
epidermal melanin production and distribution after melanocyte MC-1R binding reduces the damaging UV and visible light penetration. Afamelanotide 
binding to MC-1R on all cell types in skin also enhances DNA repair, upregulates antioxidant enzymes, and reduces production of proinflammatory cytokines 
in both the dermis and the epidermis, minimizing the PPIX-mediated damage and resulting pain. EPP, erythropoietic protoporphyria.
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with consistent effectiveness, a favorable risk–safety profile, 
and a high compliance rate for afamelanotide (Minder and 
Schneider-Yin, 2015). A recently published longitudinal 
observational study in 115 EPP patients treated with more 
than 1,023 afamelanotide implants from 2006 to June 2014 
confirmed good clinical effectiveness and safety as well as 
durably improved quality-of-life scores under these long-
term conditions (Biolcati et al., 2015).
The approval of afamelanotide by the European Medicines 
Agency in late 2014 can be regarded as a breakthrough for 
a-MSH in clinical medicine. This success is based on the 
year-long commitment of many scientists but also on the 
critical input of others (Clinuvel) at later stages. Indeed, EPP 
still cannot be cured by afamelanotide, and thus a long-term 
or even a lifelong management strategy for these patients 
is mandatory. Additional studies will be needed to further 
define the mode of action of afamelanotide in the skin of 
patients with EPP. For example, is the beneficial effect of 
afamelanotide in EPP patients due simply to increased epi-
dermal pigmentation or is it related to reduced oxidative 
stress and nociception (Figure 1)? Is porphyrin metabolism 
perhaps directly targeted by a-MSH? It will be fascinating to 
answer these questions in the future and also to learn more 
about other possible indications for such a-MSH analogs.
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